Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow

Mahesh Kate, Negar Asdaghi, Laura C. Gioia, Brian Buck, Sumit R. Majumdar, Thomas Jeerakathil, Ashfaq Shuaib, Derek Emery, Christian Beaulieu, Kenneth Butcher

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effect of blood pressure (BP) reduction on cerebral blood flow (CBF) in acute ischemic stroke is unknown. We measured regional CBF with perfusion-weighted MRI before and after BP treatment in a three-armed non-randomized prospective controlled trial. Treatment arm assignment was based on acute mean arterial pressure (MAP). Patients with (MAP) >120 mmHg (n = 14) were treated with intravenous labetalol and sublingual (SL) nitroglycerin (labetalol group). Those with MAP 100–120 mmHg (n = 17) were treated with SL nitroglycerin (0.3 mg) (‘NTG Group’) and those with baseline MAP<100 mmHg (n = 18) were not treated with antihypertensive drugs (untreated group). Forty-nine patients (18 female, mean age 65.3 ± 12.9 years) were serially imaged. Labetalol reduced MAP by 12.5 (5.7–17.7) mmHg, p = 0.0002. MAP remained stable in the NTG (6.0 (0.4–16, p = 0.3) mmHg and untreated groups (−0.3 (−2.3–7.0, p = 0.2) mmHg. The volume of total hypoperfused tissue (CBF<18 ml/100 g/min) did not increase after labetalol (−1.1 ((−6.5)–(−0.2)) ml, p = 0.1), NTG (0 ((−1.5)–4.5) ml, p = 0.72), or no treatment 0.25 ((−10.1)–4.5) ml, p = 0.87). Antihypertensive therapy, based on presenting BP, in acute stroke patients was not associated with an increased volume of total hypoperfused tissue.

Original languageEnglish (US)
JournalJournal of Cerebral Blood Flow and Metabolism
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cerebrovascular Circulation
Labetalol
Arterial Pressure
Stroke
Blood Pressure
Nitroglycerin
Antihypertensive Agents
Magnetic Resonance Angiography
Regional Blood Flow
Therapeutics

Keywords

  • acute ischemic stroke
  • Blood pressure
  • cerebral blood flow
  • labetalol
  • nitroglycerin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow. / Kate, Mahesh; Asdaghi, Negar; Gioia, Laura C.; Buck, Brian; Majumdar, Sumit R.; Jeerakathil, Thomas; Shuaib, Ashfaq; Emery, Derek; Beaulieu, Christian; Butcher, Kenneth.

In: Journal of Cerebral Blood Flow and Metabolism, 01.01.2018.

Research output: Contribution to journalArticle

Kate, Mahesh ; Asdaghi, Negar ; Gioia, Laura C. ; Buck, Brian ; Majumdar, Sumit R. ; Jeerakathil, Thomas ; Shuaib, Ashfaq ; Emery, Derek ; Beaulieu, Christian ; Butcher, Kenneth. / Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow. In: Journal of Cerebral Blood Flow and Metabolism. 2018.
@article{58be853b1d6340e08ea14ad5187f88d3,
title = "Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow",
abstract = "The effect of blood pressure (BP) reduction on cerebral blood flow (CBF) in acute ischemic stroke is unknown. We measured regional CBF with perfusion-weighted MRI before and after BP treatment in a three-armed non-randomized prospective controlled trial. Treatment arm assignment was based on acute mean arterial pressure (MAP). Patients with (MAP) >120 mmHg (n = 14) were treated with intravenous labetalol and sublingual (SL) nitroglycerin (labetalol group). Those with MAP 100–120 mmHg (n = 17) were treated with SL nitroglycerin (0.3 mg) (‘NTG Group’) and those with baseline MAP<100 mmHg (n = 18) were not treated with antihypertensive drugs (untreated group). Forty-nine patients (18 female, mean age 65.3 ± 12.9 years) were serially imaged. Labetalol reduced MAP by 12.5 (5.7–17.7) mmHg, p = 0.0002. MAP remained stable in the NTG (6.0 (0.4–16, p = 0.3) mmHg and untreated groups (−0.3 (−2.3–7.0, p = 0.2) mmHg. The volume of total hypoperfused tissue (CBF<18 ml/100 g/min) did not increase after labetalol (−1.1 ((−6.5)–(−0.2)) ml, p = 0.1), NTG (0 ((−1.5)–4.5) ml, p = 0.72), or no treatment 0.25 ((−10.1)–4.5) ml, p = 0.87). Antihypertensive therapy, based on presenting BP, in acute stroke patients was not associated with an increased volume of total hypoperfused tissue.",
keywords = "acute ischemic stroke, Blood pressure, cerebral blood flow, labetalol, nitroglycerin",
author = "Mahesh Kate and Negar Asdaghi and Gioia, {Laura C.} and Brian Buck and Majumdar, {Sumit R.} and Thomas Jeerakathil and Ashfaq Shuaib and Derek Emery and Christian Beaulieu and Kenneth Butcher",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/0271678X18774708",
language = "English (US)",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow

AU - Kate, Mahesh

AU - Asdaghi, Negar

AU - Gioia, Laura C.

AU - Buck, Brian

AU - Majumdar, Sumit R.

AU - Jeerakathil, Thomas

AU - Shuaib, Ashfaq

AU - Emery, Derek

AU - Beaulieu, Christian

AU - Butcher, Kenneth

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The effect of blood pressure (BP) reduction on cerebral blood flow (CBF) in acute ischemic stroke is unknown. We measured regional CBF with perfusion-weighted MRI before and after BP treatment in a three-armed non-randomized prospective controlled trial. Treatment arm assignment was based on acute mean arterial pressure (MAP). Patients with (MAP) >120 mmHg (n = 14) were treated with intravenous labetalol and sublingual (SL) nitroglycerin (labetalol group). Those with MAP 100–120 mmHg (n = 17) were treated with SL nitroglycerin (0.3 mg) (‘NTG Group’) and those with baseline MAP<100 mmHg (n = 18) were not treated with antihypertensive drugs (untreated group). Forty-nine patients (18 female, mean age 65.3 ± 12.9 years) were serially imaged. Labetalol reduced MAP by 12.5 (5.7–17.7) mmHg, p = 0.0002. MAP remained stable in the NTG (6.0 (0.4–16, p = 0.3) mmHg and untreated groups (−0.3 (−2.3–7.0, p = 0.2) mmHg. The volume of total hypoperfused tissue (CBF<18 ml/100 g/min) did not increase after labetalol (−1.1 ((−6.5)–(−0.2)) ml, p = 0.1), NTG (0 ((−1.5)–4.5) ml, p = 0.72), or no treatment 0.25 ((−10.1)–4.5) ml, p = 0.87). Antihypertensive therapy, based on presenting BP, in acute stroke patients was not associated with an increased volume of total hypoperfused tissue.

AB - The effect of blood pressure (BP) reduction on cerebral blood flow (CBF) in acute ischemic stroke is unknown. We measured regional CBF with perfusion-weighted MRI before and after BP treatment in a three-armed non-randomized prospective controlled trial. Treatment arm assignment was based on acute mean arterial pressure (MAP). Patients with (MAP) >120 mmHg (n = 14) were treated with intravenous labetalol and sublingual (SL) nitroglycerin (labetalol group). Those with MAP 100–120 mmHg (n = 17) were treated with SL nitroglycerin (0.3 mg) (‘NTG Group’) and those with baseline MAP<100 mmHg (n = 18) were not treated with antihypertensive drugs (untreated group). Forty-nine patients (18 female, mean age 65.3 ± 12.9 years) were serially imaged. Labetalol reduced MAP by 12.5 (5.7–17.7) mmHg, p = 0.0002. MAP remained stable in the NTG (6.0 (0.4–16, p = 0.3) mmHg and untreated groups (−0.3 (−2.3–7.0, p = 0.2) mmHg. The volume of total hypoperfused tissue (CBF<18 ml/100 g/min) did not increase after labetalol (−1.1 ((−6.5)–(−0.2)) ml, p = 0.1), NTG (0 ((−1.5)–4.5) ml, p = 0.72), or no treatment 0.25 ((−10.1)–4.5) ml, p = 0.87). Antihypertensive therapy, based on presenting BP, in acute stroke patients was not associated with an increased volume of total hypoperfused tissue.

KW - acute ischemic stroke

KW - Blood pressure

KW - cerebral blood flow

KW - labetalol

KW - nitroglycerin

UR - http://www.scopus.com/inward/record.url?scp=85047406318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047406318&partnerID=8YFLogxK

U2 - 10.1177/0271678X18774708

DO - 10.1177/0271678X18774708

M3 - Article

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

ER -